{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:15:22Z","timestamp":1791227722237,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,3,6]],"date-time":"2014-03-06T00:00:00Z","timestamp":1394064000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1245\/s10434-014-3599-4","type":"journal-article","created":{"date-parts":[[2014,3,5]],"date-time":"2014-03-05T16:40:24Z","timestamp":1394037624000},"page":"2383-2389","source":"Crossref","is-referenced-by-count":77,"title":["Treatment of Microscopic Disease with Hyperthermic Intraoperative Intraperitoneal Chemotherapy After Complete Cytoreduction Improves Disease-Free Survival in Patients with Stage IIIC\/IV Ovarian Cancer"],"prefix":"10.1245","volume":"21","author":[{"given":"Pedro Antonio","family":"Cascales-Campos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Feliciangeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gonz\u00e1lez-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Parrilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Parrilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,6]]},"reference":[{"key":"3599_CR1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10\u20132.","journal-title":"CA Cancer J Clin"},{"key":"3599_CR2","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","volume":"374","author":"BT Hennessy","year":"2009","unstructured":"Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;374:1371\u201382.","journal-title":"Lancet"},{"key":"3599_CR3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ygyno.2010.05.025","volume":"118","author":"RE Bristow","year":"2010","unstructured":"Bristow RE, Palis BE, Chi DS, Cliby WA. The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol. 2010;118:262\u20137.","journal-title":"Gynecol Oncol"},{"key":"3599_CR4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/IGC.0b013e31819915cb","volume":"19","author":"C Marth","year":"2009","unstructured":"Marth C, Hieble S, Oberainger W, Winter R, Leodolter S, Sevelda P. Influence of department volume on survival for ovarian cancer: results from a prospective quality assurance program of the Austrian Association for Gynecologic. Int J Gynecol Cancer. 2009;19:94\u201310.","journal-title":"Int J Gynecol Cancer"},{"key":"3599_CR5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ygyno.2008.09.036","volume":"112","author":"A Bois du","year":"2009","unstructured":"du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol. 2009;112:422\u201336.","journal-title":"Gynecol Oncol"},{"key":"3599_CR6","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194\u2013200.","journal-title":"J Clin Oncol"},{"key":"3599_CR7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1272\/jnms.67.5","volume":"67","author":"PH Sugarbaker","year":"2000","unstructured":"Sugarbaker PH. It\u2019s what the surgeon doesn\u2019t see that kills the patient. J Nippon Med Sch. 2000;67:5\u20138.","journal-title":"J Nippon Med Sch"},{"key":"3599_CR8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/GCO.0b013e32831f8f32","volume":"21","author":"PH Sugarbaker","year":"2009","unstructured":"Sugarbaker PH. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer. Curr Opin Obstet Gynecol. 2009;21:15\u201324.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"3599_CR9","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1245\/s10434-006-9182-x","volume":"14","author":"TD Yan","year":"2007","unstructured":"Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomixoma peritonei. Ann Surg Oncol. 2007;14:484\u201392.","journal-title":"Ann Surg Oncol"},{"key":"3599_CR10","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737\u201343.","journal-title":"J Clin Oncol"},{"key":"3599_CR11","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/annonc\/mdl428","volume":"18","author":"TD Yan","year":"2007","unstructured":"Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18:827\u201334.","journal-title":"Ann Oncol"},{"key":"3599_CR12","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1634\/theoncologist.2008-0275","volume":"14","author":"CW Helm","year":"2009","unstructured":"Helm CW. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist. 2009;14:683\u201394.","journal-title":"Oncologist"},{"key":"3599_CR13","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12094-007-0118-0","volume":"9","author":"FC Mu\u00f1oz-Casares","year":"2007","unstructured":"Mu\u00f1oz-Casares FC, Rufi\u00e1n S, Rubio MJ, Liz\u00e1rraga E, D\u00edaz-Iglesias C, Aranda E, et al. Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals. Clin Transl Oncol. 2007;9:652\u201362.","journal-title":"Clin Transl Oncol"},{"key":"3599_CR14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ejogrb.2011.04.036","volume":"158","author":"PA Cascales","year":"2011","unstructured":"Cascales PA, Gil J, Galindo PJ, Machado F, Frutos IM, Paricio PP. Heterogeneity in patients and methods. A problem for hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol. 2011;158:361\u20132.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"3599_CR15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/ejso.2002.1380","volume":"29","author":"AA Tentes","year":"2003","unstructured":"Tentes AA, Tripsiannis G, Markakidis SK, Karanikiotis CN, Tzegas G, Georgiadis G, et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol. 2003;29:69\u201373.","journal-title":"Eur J Surg Oncol"},{"key":"3599_CR16","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248\u201359.","journal-title":"J Clin Oncol"},{"key":"3599_CR17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-1-4613-1245-1_13","volume":"81","author":"PH Sugarbaker","year":"1996","unstructured":"Sugarbaker PH. Peritoneal carcinomatosis: natural history and rational therapeutic interventions using intraperitoneal chemotherapy. Cancer Treat Res. 1996;81:149\u201368.","journal-title":"Cancer Treat Res"},{"key":"3599_CR18","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00432-009-0667-4","volume":"135","author":"TC Chua","year":"2009","unstructured":"Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol. 2009;135:1637\u201345.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3599_CR19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejso.2010.11.004","volume":"37","author":"M Deraco","year":"2011","unstructured":"Deraco M, Baratti D, Laterza B, Balestra MR, Mingrone E, Macr\u00ec A, et al. Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Eur J Surg Oncol. 2011;37:4\u20139.","journal-title":"Eur J Surg Oncol"},{"key":"3599_CR20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0960-7404(99)00007-9","volume":"7","author":"C Christophi","year":"1998","unstructured":"Christophi C, Winkworth A, Muralihdaran V, Evans P. The treatment of malignancy by hyperthermia. Surg Oncol. 1998;7:83\u201390.","journal-title":"Surg Oncol"},{"key":"3599_CR21","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1067\/msy.2002.119308","volume":"131","author":"I Takahashi","year":"2002","unstructured":"Takahashi I, Emi Y, Hasuda S, Kakeji Y, Maehara Y, Sugimachi K. Clinical application of hyperthermia combined with anticancer drugs for the treatment of solid tumors. Surgery. 2002;131:S78\u2013S84.","journal-title":"Surgery"},{"key":"3599_CR22","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","volume":"10","author":"M Markman","year":"1992","unstructured":"Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, et al. Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol. 1992;10:1485\u201391.","journal-title":"J Clin Oncol"},{"key":"3599_CR23","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s11095-011-0401-1","volume":"28","author":"W Bouquet","year":"2011","unstructured":"Bouquet W, Deleye S, Staelens S, De Smet L, Van Damme N, Debergh I, et al. Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model. Pharm Res. 2011;28:1653\u201360.","journal-title":"Pharm Res"},{"key":"3599_CR24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ygyno.2007.03.019","volume":"106","author":"JH Bae","year":"2007","unstructured":"Bae JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, et al. Treatment of ovarian cancer with paclitaxel-or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol. 2007;106:193\u2013200.","journal-title":"Gynecol Oncol"},{"key":"3599_CR25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s12094-009-0438-3","volume":"11","author":"FC Mu\u00f1oz-Casares","year":"2009","unstructured":"Mu\u00f1oz-Casares FC, Rufi\u00e1n S, Rubio MJ, et al. The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol. 2009;11:753\u20139.","journal-title":"Clin Transl Oncol"},{"key":"3599_CR26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/gyno.2000.5926","volume":"78","author":"AL Covens","year":"2000","unstructured":"Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol. 2000;78:269\u201374.","journal-title":"Gynecol Oncol"},{"key":"3599_CR27","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0090-8258(03)00342-1","volume":"90","author":"ML Berman","year":"2003","unstructured":"Berman ML. Future directions in the surgical management of ovarian cancer. Gynecol Oncol. 2003;90:S33\u20139.","journal-title":"Gynecol Oncol"},{"key":"3599_CR28","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.1200\/JCO.2005.02.1287","volume":"23","author":"SC Crawford","year":"2005","unstructured":"Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. J Clin Oncol. 2005;23:8802\u201311.","journal-title":"J Clin Oncol"},{"key":"3599_CR29","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1002\/cncr.24317","volume":"115","author":"SF Adams","year":"2009","unstructured":"Adams SF, Levine DA, Cadungog MG, Hammond R, Facciabene A, Olvera N, et al. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous EOC. Cancer. 2009;115:2891\u2013902.","journal-title":"Cancer"},{"key":"3599_CR30","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1245\/s10434-012-2446-8","volume":"19","author":"SJ Chang","year":"2012","unstructured":"Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol. 2012;19:4059\u201367.","journal-title":"Ann Surg Oncol"},{"key":"3599_CR31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ygyno.2010.07.032","volume":"119","author":"M Peiretti","year":"2010","unstructured":"Peiretti M, Zanagnolo V, Aletti GD, Bocciolone L, Colombo N, Landoni F, et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Single institution experience. Gynecol Oncol. 2010;119:259\u201364.","journal-title":"Gynecol Oncol"},{"key":"3599_CR32","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.1991.9.7.1138","volume":"9","author":"GA Omura","year":"1991","unstructured":"Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol. 1991;9:1138\u201350.","journal-title":"J Clin Oncol"},{"key":"3599_CR33","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","volume":"103","author":"DS Chi","year":"2006","unstructured":"Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103:559\u201364.","journal-title":"Gynecol Oncol"},{"key":"3599_CR34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.AOG.0000192407.04428.bb","volume":"107","author":"GD Aletti","year":"2006","unstructured":"Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107:77\u201385.","journal-title":"Obstet Gynecol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-3599-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-014-3599-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-3599-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T05:16:07Z","timestamp":1565241367000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-014-3599-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,6]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["3599"],"URL":"https:\/\/doi.org\/10.1245\/s10434-014-3599-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,6]]}}}